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Emerging evidence suggests that altered neural connectivity, particularly at the 
level of synaptic connections, contributes to the pathology of many neurodevelopmental 
and neurodegenerative diseases. For instance, post-mortem Autistic patient brain 
samples have increased numbers of excitatory to inhibitory synaptic connections, referred 
to as an E/I imbalance [42]. Contrastingly, post-mortem brain samples from patients 
diagnosed with Alzheimer’s disease have decreased numbers of synaptic connections 
[42]. In order to understand the mechanisms that underlie the formation of these synaptic 
circuits, we develop 3-D human cortical organoids (‘mini-brains’) from human-induced 
pluripotent stem cells (hIPSCs).  
 
Previous research demonstrates that rearrangements of the actomyosin 
cytoskeleton drive neural circuit formation, in particular the development and maturation 
of actin-enriched spines at excitatory synapses. This thesis work investigates how 
pharmacological regulation of actomyosin activity affects neuronal connectivity during 
neurite formation in 2-D and excitatory synapse formation in 3-D ‘mini-brains’. The Rho-
 
Kinase (ROCK) inhibitor, Y-27632, both inhibits non-muscle myosin II (NM-II) and leads 
to a corresponding increase in Rac-driven actin polymerization. In 2-D, Y-27632 promotes 
neurite formation. Specifically, Y-27632 increases the number, length, and branching of 
neurites in hIPSC-derived neurons. Furthermore, Y-27632 increases neurite persistence, 
while decreasing neurite protrusion and retraction rates. However, in 3-D, acute Y-27632 
treatment increases excitatory synapse area, consistent with an increase in Rac-driven 
actin polymerization [39].  
 
Thus, Y-27632 increases both neurite outgrowth and excitatory synapse formation 
and may serve as a potential therapeutic for neurodegenerative diseases associated with 
synapse loss such as Alzheimer’s disease. This study demonstrates the need for 
physiologically-relevant brain models, such as 3-D cortical organoids, to assess the 
impact of drug therapies on developing neural circuits to potentially treat 
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Autism spectrum disorder (ASD) is a genetically complex heterogeneous 
neurodevelopmental disorder in which patients exhibit social deficits in both verbal and 
non-verbal forms of communication and display restricted and repetitive behaviors [2]. 
More than 3.5 million Americans live with ASD, costing the United States nearly $250 
billion annually in ASD-related services [2]. Most alarmingly, ASD is also the fastest 
growing developmental disability in the United States [45]. The prevalence of ASD in the 
United States has increased from an estimated 1 in 150 births in 2000 to a staggering 1 
in 68 births in 2010 and 1 in 59 births in 2014 [3, 4, 45]. Unfortunately, there is no cure 
for ASD although early diagnosis and prevention can improve symptoms [2].  Moreover, 
there is no known single cause of ASD, but it is generally accepted that ASD is caused 
by abnormalities in brain structure and/or function [2]. Most recent evidence suggests that 
altered neural connectivity, particularly at the level of synaptic connections, contributes to 
the pathology of ASD. Specifically, ASD patients have increased densities of dendritic 
spines and an increased ratio of excitatory to inhibitory synaptic connections, referred to 
as an E/I imbalance [42]. In this study we explore a potential ASD therapeutic, Y-27632, 
due to its possible role of decreasing these abnormalities by altering the formation and 
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Altered Dendritic Spine Density and Morphology  
 
Dendritic spines function as the primary sites of excitatory neurotransmission, 
underlying learning and memory formation [60]. These actin-enriched spines synapse 
with pre-synaptic axon terminals, mediating electrochemical communication between 
neurons to form circuits that support normal brain development and cognitive function 
[60].  However, altered synaptic plasticity, in particular the density and morphology of 
dendritic spines, contributes to neurodevelopmental and neurodegenerative diseases 
such as Autism and Alzheimer’s Disease [42].  
 
In early post-natal development, a robust increase in dendritic spines is refined in 
an activity-dependent manner to strengthen specific neuronal connections while 
eliminating others, ultimately resulting in a relatively steady-state level of synaptic 
connections that persists throughout adulthood [Diagram 1, black] [42].  In 
neurodevelopmental disorders, such as Autism, defects in eliminating synaptic 
connections may result in the elevated dendritic spine density observed in post-mortem 
patient brain samples and animal models [Diagram 1, pink] [42]. Conversely, in 
neurodegenerative disorders, such as Alzheimer’s Disease, excessive spine loss 
promotes cognitive decline prior to neuronal cell death [Diagram 1, blue] [42].  
 
Identification of the mechanisms that sculpt specific stages of synapse formation, 
maturation, pruning, and activity-dependent remodeling will allow for therapeutic 
intervention at discrete developmental and pathological stages. Thus, it is imperative to 
understand the regulatory mechanisms that remodel synaptic architecture during 
development and in response to excitatory/inhibitory activity.    
























Diagram 1. Putative Lifetime Trajectory of Dendritic Spine Number. In normal 
subjects (black), spine numbers increase before and after birth; spines are selectively 
eliminated during childhood and adolescence to adult levels. In ASD (pink), exaggerated 
spine formation or incomplete pruning may occur in childhood leading to increased spine 
numbers. In schizophrenia (green), exaggerated spine pruning during late childhood or 
adolescence may lead to the emergence of symptoms during these periods. In 
Alzheimer’s disease (blue), spines are rapidly lost in late adulthood, suggesting perturbed 
spine maintenance mechanisms that may underlie cognitive decline. Bars across the top 
indicate the period of emergence of symptoms and diagnosis. (Figure from Penzes et al. 
[42], legend modified)  
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Actin Dynamics Underlie Dendritic Spine Maturation and Synapse Formation 
 
Dendritic spines consist primarily of actin and actin-associated proteins [Diagram 
2] [17]. During spinogenesis, spines emerge from patches of branched actin along 
dendritic shafts [Diagram 2A] as filopodia-like spine precursors with anti-parallel actin 
filaments that associate with the actin motor protein, non-muscle myosin II (NM-II) 
[Diagram 2B] [17, 27]. Epidermal growth factor receptor kinase substrate 8 (Eps8) inhibits 
this process by capping the ends of barbed actin, preventing further actin polymerization 
and lengthening of spine precursors [Diagram 2A] [17, 34]. Conversely, 
enabled/vasodilator-stimulated phosphoprotein (Ena/VASP) family proteins may induce 
the formation of filopodia-like spine precursors due to their anti-capping properties 
[Diagram 2A] [8, 17].  
 
These filopodia-like spine precursors subsequently [Diagram 2B] mature into thin 
spines with a distinct spine head and neck [Diagram 2C] [17, 59].  Further excitatory 
stimulation leads to spine maturation into a polarized mushroom-shape, consisting of a 
constricted neck and bulbous spine head with a post-synaptic density (PSD) that clusters 
neurotransmitter receptors across from the pre-synaptic axon terminal [Diagram 2D] [17]. 
Actin-associated proteins exhibit preferential localization to discrete regions within mature 
spines [27]. For example, Arp2/3 and capping protein, which regulate actin filament 
assembly, preferentially localize to the spine head, while myosin-II, which bundles and 
contracts actin filaments, preferentially localizes to the spine neck and lower portion of 
the spine head [27]. Despite these detailed insights into the molecular architecture of the 
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spine, the regulatory mechanisms that drive actin dynamics at specific stages of synaptic 
development are not well understood.  
  
















Diagram 2. Actin Regulatory Mechanisms During Spine Development and 
Plasticity. (A) Initiation of the dendritic filopodium and its elongation. Eps8 inhibits 
filopodia initiation by its capping activity. Ena/VASP proteins may induce filopodia 
elongation from Arp2/3 complex–generated branched filaments by anti-capping the actin 
barbed ends. (B) mDia2 promotes actin filament polymerization in the filopodium tip. The 
factors driving actin filament polymerization in the base of filopodia remain to be identified. 
(C) Extensive actin branching occurs at the filopodium tip and the spine head begins to 
form. The rate of actin assembly is now increased and the large Arp2/3-nucleated 
branched actin filament network leads to enlargement of the spine head. The function of 
ADF/cofilins, in addition to replenishing the cytoplasmic actin monomer pool in neurons, 
is to control the proper length of actin filaments and thus to prevent formation of abnormal 
protrusions from spine heads. (D) Mature spines are still dynamic but maintain their 
overall morphology. Myosin II–dependent contractility and cross-linking of actin filaments 
further modulate the shape of the spine head. (Figure from Hotulainen et al. [17], legend 
modified) 
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Master Regulators of the Actin Cytoskeleton 
 
RhoGTPases regulate actin cytoskeleton organization and dynamics in diverse 
cellular processes, including dendritic spine morphogenesis [40, 54]. Coordinated activity 
of the small RhoGTPases, RhoA, Rac1, and Cdc42, orchestrate synaptic development 
and plasticity [15, 44]. Rac1 and Cdc42-driven actin polymerization regulates spine 
precursor formation and elongation through actin regulatory proteins, such as profilin and 
LIM-Kinase1 (LIMK) [18, 20, 33]. However, Rac1/Cdc42-driven actin polymerization also 
promotes spine head and post-synaptic density (PSD) expansion underlying synaptic 
strengthening [11, 15, 20, 52].  Conversely, RhoA antagonizes spine precursor formation, 
but is required for synaptic maturation via activation of the actin motor protein, NM-II, 
which polarizes the spine into the mature mushroom-shape morphology, although further 
NM-II activity may cause spine and dendrite retraction [Diagram 3] [16, 33, 39, 44].  
 
Proper regulation of RhoGTPase signaling pathways is crucial for the consolidation 
and persistence of long-term potentiation (LTP) underlying learning and memory 
formation [38]. For example, loss of Rac1/Cdc42 effector kinases, PAK3 or LIMK1, alters 
spine morphology and LTP, resulting in non-syndromic mental retardation and Williams 
Syndrome, respectively [38, 53].  Thus, RhoGTPase-mediated spine morphological 
changes support normal neuronal function underlying cognitive abilities.  
 
In addition to these downstream regulators, small RhoGTPases are themselves 
regulated due to their low intrinsic GTPase activity [14]. Guanine nucleotide exchange 
factors (GEFs) promote the exchange of GDP for GTP, activating RhoGTPases, while 
GTPase activating proteins (GAPs) promote GTP hydrolysis to GDP, resulting in 
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RhoGTPase inactivation [14]. Similar to downstream effectors, mutations in RhoGTPase 
regulators, such as the Rac1 GEF, β-PIX, or RhoA GAP, oligophrenin-1, result in 
neurodevelopmental disorders, such as non-syndromic mental retardation [38].  
 
 Recent studies have begun to delineate when specific RhoGTPase regulators 
function in synaptic development. For example, the Rac1 GEF β-PIX promotes dendritic 
spine initiation while the Cdc42 GEF Frabin and RhoA GAP oligophrenin-1 stimulate 
spine precursor elongation [33].  Furthermore, a novel Rac1 GAP, ArhGAP23, functions 
specifically to promote stabilization of the mature mushroom-shape spine [33]. These 
findings begin to address how specific RhoGTPases and their regulators function 
temporally within dendritic spines to shape brain development and how their 
misregulation may contribute to neurodevelopment disorders, such as Autism.    
  
























Diagram 3. NM-II Regulates Neuronal Plasticity. NM-II drives dynamic changes in 
neuronal morphology, including changes in dendritic spine formation and maturation. At 
the post-synaptic spine, NM-II drives changes in actin organization that regulate spine 
and PSD morphology and size, whereas, on the pre-synaptic side, NM-II participates in 
synaptic vesicle recycling. The absence or inhibition of NM-II activity results in dynamic 
‘filopodia-like’ spine precursors and prevents spine maturation. In contrast, NM-II activity 
drives spine and PSD maturation, although further NM-II activity might result in spine and 
even dendrite retraction. (Figure adapted from Newell-Litwa et al. [40], legend modified) 
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Y-27632: A Potential ASD Therapeutic  
 
 Given our current understanding of RhoGTPase regulation of actin-driven dendritic 
spine maturation and synapse formation, it is hypothesized that downregulation of NM-II 
may decrease the density of mature mushroom-shaped spines and lower E/I imbalances 
in ASD patients. As mentioned previously, NM-II activity is necessary for dendritic spine 
maturation and synapse formation due to its polarization of the dendritic spine [Diagram 
3] [16, 33, 39, 44]. Specifically, NM-II contracts actin filaments into actomyosin filament 
bundles, known as stress fibers [Diagram 4] [6, 14, 56]. These stress fibers, located 
mainly in the spine neck and lower portion of the spine head, contract actin filaments of 
filopodia-like spine precursors to create spines of the mature mushroom-shaped 
morphology, leading to synapse formation [16, 33, 39, 44]. Thus, if NM-II activity was 
downregulated, less mature mushroom-shaped spines may form, leading to the formation 
of less excitatory synapses. To test this hypothesis, the Rho-Kinase (ROCK) inhibitor Y-
27632 was utilized to decrease NM-II activity [Diagram 4].  
 
 ROCK is a serine/threonine effector kinase of the RhoGTPase RhoA that activates 
NM-II by phosphorylation of its myosin regulatory light chain (RLC) [1] [Diagram 4]. There 
are two ROCK isoforms, ROCK1 and ROCK2, which phosphorylate and activate NM-II. 
Specifically, ROCK1 diphosphorylates threonine 18 and serine 19 residues of RLC, while 
ROCK2 monophosphorylates serine 19 of RLC [39]. This difference in phosphorylation 
underlies the distinctive functional roles of ROCK1 and ROCK2. In ROCK2 knockdown 
experiments, ROCK1 activity alone produces stable stress fibers that drive PSD 
maturation of dendritic spines and define the rear of a cell. [16, 39, 55]. However, in 
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ROCK1 knockdown experiments, ROCK2 activity alone leads to the formation of less 
stable stress fibers that produce filopodia-like dendritic spine precursors with smaller 
PSDs, but promote focal adhesion formation in migratory cell protrusions [16, 39, 55]. 
Both ROCK1 and ROCK2 further increase NM-II activity by inhibition of myosin light chain 
phosphatase (MLCP), a protein that inactivates NM-II by removal of phosphate groups 
from the RLC of NM-II [Diagram 4] [24]. Therefore, a ROCK inhibitor decreases NM-II 
activity by decreasing RLC phosphorylation and increasing MLCP-mediated RLC 
dephosphorylation.  
 
The effects of ROCK inhibition on neurite formation have been well-studied. 
Particularly, ROCK inhibition has been shown to increase neurite outgrowth in cultured 
human NT2 cells [29, 46], human PC-12 cells [36, 57], and mouse neural stem cells [13, 
21]. Together, these studies point to a ROCK inhibitor-mediated dose-dependent and 
time-dependent increase in neural generation and neurite length. Given these findings, 
ROCK inhibitors may serve as a potential therapeutic for nerve regeneration [28, 51]. 
Despite our current understanding of ROCK inhibition on neurite formation, less is known 
in the context of dendritic spines. Y-27632-mediated ROCK inhibition has been shown to 
create filopodia-like spines in rat hippocampal neurons [16], but further experiments are 
needed to determine how this altered dendritic spine morphology is affecting synaptic 
connections. Furthermore, we need a physiologically-relevant system to address the role 
of Y-27632 in both neurite formation and spine morphogenesis.  
 
In this thesis work, we expand on the current knowledge of ROCK inhibition on 
early neurite formation in a human-induced pluripotent stem cell (hIPSC)-derived neuron 
   
12 
model in 2-D. In particular, we explore the effects of Y-27632-mediated ROCK inhibition 
on neurite formation, elongation, and branching. Additionally, we investigate the neurite 
dynamics of differentiating cells to better understand the mechanisms underlying these 
Y-27632-mediated differences in neurite outgrowth.   
 
Lastly, we are the first to study Y-27632 in a more physiologically-relevant and 
novel 3-D model, human cortical organoids (‘mini-brains’), to better recapitulate 
neurodevelopment of the human brain. Specifically, we investigate the effects of Y-27632-
















































Diagram 4. Inhibition of NM-II Activation Causes Less Actomyosin Filament Bundle 
Formation. (A) ROCK phosphorylates the RLC of NM-II, forming pRLC, causing 
activation of NM-II. Therefore, Y-27632 mediated ROCK inhibition leads to less pRLC and 
NM-II activity.  The myosin head of NM-II moves toward the barbed(+) ends of anti-parallel 
actin filaments, contracting the filaments towards their pointed(-) ends. This forms 
actomyosin filament bundles capable of contractile forces. Thus, Y-27632-mediated 
ROCK inhibition inhibits NM-II activation, leading to the formation of less actomyosin 
filament bundles.  (Figure adapted from Newell-Litwa et al. [40], legend modified) 




Hypothesis #1 (2-D): Y-27632-mediated ROCK inhibition increases neural complexity in 
hIPSC-derived neurons. In particular, Y-27632 promotes the formation of more neurites 
that are longer in length with increased branching. 
 
Hypothesis #2 (3-D): Y-27632-mediated ROCK inhibition increases neural complexity in 
hIPSC-derived ‘mini-brains’ as in 2-D hIPSC-derived neurons. Furthermore, Y-27632 
reduces the formation of mature mushroom-shaped spines, resulting in decreased 
























The four neurotypic control skin fibroblast cell lines BJ (control cell line #1), 9319 
(control cell line #2), WTC-11 (control cell line #3), and 7545 (control cell line #4) were 
reprogrammed into human-induced pluripotent stem cells (hIPSCs) with the addition of 
Yamanaka transcription factors Oct3/4, Sox2, Klf4, and c-Myc [50] using the Invitrogen™ 
CytoTune™-iPS 2.0 Sendai Reprogramming Kit. hIPSCs from control cell lines #1 and 
#2 were generated by Kristen Brennand in the lab of Dr. Fred Gage at the Salk Institute, 
while hIPSCs from control cell line #4 were generated in the lab of Dr. McConnell at the 
University of Virginia School of Medicine. Moreover, hIPSCs from control cell line #3 were 
generated in the lab of Dr. Bruce Conklin at the Gladstone Institute of Cardiovascular 
Disease. Beta actin (ActB) of control cell line #3 hIPSCs was later endogenously tagged 
with monomeric enhanced green fluorescent protein (mEGFP) using CRISPR/Cas9 
technology at the Allen Institute for Cell Science, creating ActB mEGFP hIPSCs. Note, 
control cell lines #1 and #2 hIPSCs were obtained under a material transfer agreement 
(MTA) with Kristen Brennand and the Salk Institute, while control cell lines #3 and #4  




Neural progenitor cells (NPCs) were generated from control cell lines #1, #2, and 
#3 hIPSCs through an embryoid body protocol as described by Brennand et al. [5]. In 
summary, 1mL/well of PluriSTEM™ Dispase-II Solution was used to dissociate hIPSCs 
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from Corning™ Costar™ ultra-low attachment 6-well plastic plates to form floating 
embryoid bodies. Floating embryoid bodies were then cultured in 2mL/well of Gibco® 
Essential 6™ Medium for one day. The next day media was switched to 2mL/well of 
Gibco® Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) + 
GlutaMAX supplemented with 1% of Gibco® N-2, 2% of Gibco® B-27™ without vitamin 
A, 10μM of StemMACS™ SB431542, and 100nM of STEMCELL™ TECHNOLOGIES 
LDN193189 inside a tissue culture incubator set at 5% CO2 and 37ºC. After 7 days in 
culture, embryoid bodies were plated onto Sigma Aldrich® Poly-L-Ornithine (pORN) and 
Corning™ laminin-coated Bio-One® CELLSTAR® 6-well plastic tissue culture plates. 
Embryoid bodies were then cultured in the same media for an additional 7 days until 
neural rosettes formed. Lastly, 1mL/well of STEMdiff™ Neural Rosette Selection Reagent 
was used to dissociate neural rosettes, forming NPCs. Note, control cell lines #1 and #2 
NPCs were generated by Kristen Brennand in the lab of Dr. Fred Gage at the Salk 
Institute, while control cell line #3 NPCs were generated by lab technician Brenna Kirk in 
the lab of Dr. Litwa at the Brody School of Medicine.  
 
NPCs were grown on Sigma Aldrich® pORN and Corning™ laminin-coated Bio-
One® CELLSTAR® 6-well plastic tissue culture plates for the first four passages inside a 
tissue culture incubator set at 5% CO2 and 37ºC in 2mL/well of NPC media, which consists 
of Gibco® DMEM/F-12 + GlutaMAX, 1% of Gibco® N-2, 2% of Gibco® B-27™ without 
vitamin A, 1μg/mL of Corning™ laminin, and 20ng/mL of PeproTech® basic fibroblast 
growth factor (bFGF). After four passages, NPCs were grown on Corning™ matrigel-
coated Greiner Bio-One® CELLSTAR® 6-well plastic tissue culture plates instead. NPC 
media was replaced every other day and cells were grown to a confluency of no more 
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than 80% before subsequent cell splitting. During cell passaging, 500μL/well of StemPro®  
Accutase® from Gibco® by Life Technologies™ was used to lift cells from plates. NPCs 
used for experiments had a passage number below 15 and were at least 90% viable as 
determined by the Countess® Automated Cell Counter from Invitrogen™.  
 
Differentiation of hIPSC-derived NPCs into Neurons 
 
Following overnight plating, 200,000 NPCs per well were differentiated at 37ºC and 
5% CO2 inside a tissue culture incubator on Sigma Aldrich® pORN and Corning™ laminin 
coated Bio-One® CELLSTAR® 6-well plastic tissue culture plates for 24 hours in 
2mL/well of neural differentiation media, consisting of Gibco® DMEM/F-12 + GlutaMAX, 
1% of Gibco® N-2, 2% of Gibco® B-27™ with vitamin A, 20ng/mL of Shenandoah 
Biotechnology Inc™ BDNF, 20ng/mL of Shenandoah Biotechnology Inc™ glial cell-
derived neurotrophic factor (GDNF), 400uM of Sigma Aldrich® cyclic adenosine 
monophosphate (cAMP), and 200nM of ascorbic acid from Fisher Scientific 
supplemented with 0μM, 5μM, 10μM, 25μM, or 50μM of Y-27632. Experiments were 
completed with control cell lines #1, #2, and #3 NPCs. Note for time lapse experiments, 
100,000 NPCs per well were differentiated on Sigma Aldrich® pORN and Corning™ 
laminin coated MatTek® 6-well glass bottom tissue culture plates at 37ºC and 5% CO2 
inside the ZEISS LSM 700 Confocal onstage incubator. Time-lapse experiments were 
completed with control cell line #3 NPCs only, since the endogenous GFP enabled 











Human cortical organoids (‘mini-brains’) were generated from control cell line #4 
hIPSCs by lab technician Brenna Kirk in the lab of Dr. Litwa at the Brody School of 
Medicine as described by Pasca et al. [41]. In summary, hiPSCs were added to 
Corning™ Costar™ ultra-low attachment 6-well plastic plates in 4mL/well of Gibco® 
Knockout™ Serum Replacement based media, which caused hIPSCs to aggregate into 
spheroids. 5μM of Dorsomorphin from BioVision Incorporated and 10μM of 
StemMACS™ SB431542 by Miltenyi Biotec were then added to the media to inhibit 
bone morphogenetic protein (BMP) and transforming growth factor beta (TGF-ß) 
signaling pathways, leading to neural induction. After 6 days, the suspended spheroids 
were moved to 2mL/well of Gibco® Neurobasal™- A media supplemented with 2% of 
Gibco® B-27™ without vitamin A, 20ng/mL of PeproTech® bFGF, and 20ng/mL of 
PeproTech® epidermal growth factor (EGF). Supplemented neurobasal media was 
changed every day for 10 days and every other day for the following 9 days. On day 25, 
bFGF and EGF were replaced with 20ng/mL of brain-derived neurotrophic factor 
(BDNF) and 20ng/mL of neurotrophic factor 3 (NT3) from Shenandoah Biotechnology 
Inc™ to promote neural differentiation of NPCs within the ‘mini-brain.’ Note, media was 
changed every other day for 18 days. 4mL/well of non-supplemented Gibco® 
Neurobasal™- A media was used from day 43 onwards, changing media every 4 days. 
After 89 days, ‘mini-brains’ were either treated with 10μM of the Rho-Kinase (ROCK) 
inhibitor Y-27632 from Selleck for 24 hours or left untreated. ‘Mini-brains’ were then 
harvested for protein or fixed for immunofluorescence staining on day 90. Note, ‘mini-
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brains’ were cultured inside a tissue culture incubator set at 5% CO2 and 37ºC for the 
entire process. For a schematic of ‘mini-brain’ generation, please see Diagram 5.  
  















Diagram 5. Generation of hIPSC-derived ‘Mini-brains’. Skin fibroblasts samples from 
neurotypic control patients were reprogrammed into induced pluripotent stem cells with 
the addition of Yamanaka transcription factors. Induced pluripotent stem cells then 
aggregated to form embryoid bodies. Lastly, the ectoderm of embryoid bodies were 
selected for and differentiated into 3-D cerebral organoids.  
 
  




hIPSC-derived neurons were fixed after 24 hours of neural differentiation for 20 
minutes at room temperature with 4% formaldehyde with 4% sucrose in 1X phosphate-
buffered saline (PBS). Fixed cells were then permeabilized for 2 minutes at room 
temperature with 0.1% Triton X-100 in 1X PBS. Next, cells were blocked with 5% goat 
serum in 1X PBS for 30 minutes. Blocked cells were then incubated in diluted primary 
antibodies in 2% goat serum overnight at 4ºC. After overnight primary antibody 
incubation, cells were incubated in diluted Alexa Fluor® secondary antibodies in 2% goat 
serum in the dark for one hour at room temperature. For more information about primary 
and secondary antibodies used, please see Tables 1 and 2 in Appendix A. Lastly, the 
nuclei of cells were stained using DAPI staining solution from GeneTex® for 10 minutes 
at room temperature.  
 
‘Mini-brains’ were fixed with 4% formaldehyde in 1X PBS at 4ºC overnight. The 
following day, fixed ‘mini-brains’ were placed in 30% sucrose in 1X PBS at 4ºC overnight. 
Joani Zary, a research specialist in the Department of Anatomy and Cell Biology at the 
Brody School of Medicine, then embedded the ‘mini-brains’ into a disposable base mold 
from Simport Scientific Inc. with O.C.T. compound from Sakura Finetek USA Inc. and 
froze them with dry ice/2-methyl butane slush from Fisher Scientific. Subsequently, Joani 
sectioned the ‘mini-brains’ 10μm thick on a Richard-Allan Scientific cryostat. Finally, she 
thaw mounted sections onto 2% 3-Aminopropyl Triethoxysilane treated slides. Slides of 
cryosectioned ‘mini-brains’ were assembled onto cover plates with 0.2% Triton X-100 in 
1X PBS and placed into a Sequenza rack. Next, ‘mini-brains’ were blocked with 
   
22 
120μL/slide of 5% goat serum in 1X PBS for 30 minutes. Blocked mini-brains were then 
incubated in 120μL/slide of various primary antibodies in 2% goat serum overnight at 4ºC. 
After overnight primary antibody incubation, slides were incubated in 120μL/slide of 
diluted Alexa Fluor® secondary antibodies in 2% goat serum in the dark for one hour at 
room temperature. For more information about primary antibodies and secondary 
antibodies used, please see Tables 1 and 2 in Appendix A.  Lastly, No. 1 Fisherbrand® 
cover glasses were affixed to slides with Fluoro-Gell II with DAPI from Electron 




Representative images were taken of fixed hIPSC-derived neurons using DAPI 
and Invitrogen Texas Red light cubes in the EVOS™ FL Auto 2 at 20X total magnification. 
For quantification, 100 fields of each well of immunofluorescently stained hIPSC-derived 
neurons were imaged at 10X total magnification and simultaneously analyzed using the 
Neuronal Profiling Assay V4.2 of the Thermo Scientific™ CellInsight™ CX5 High Content 
Screening Platform. In Y-27632-mediated ROCK inhibiton confirmation experiments, cell 
features cellbodyspotavginten and neuritespotavginten were selected to measure the 
average intensity of both phosphorylated (S19/S20) myosin light chain/regulatory light 
chain (pRLC) and myosin light chain/regulatory light chain (RLC) within neurites and cell 
bodies of neurons. Afterwards, the average neurite intensity of pRLC within each neuron 
was divided by the average neurite intensity of RLC. Likewise, the cell body intensity of 
pRLC within each neuron was divided by the cell body intensity of RLC. Additionally, the 
cell features neuritetotalcount, neuriteavglength, and branchpointavgcount were utilized 
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to measure total number, average length, and average number of branch points of 
neurites within neurons.  
 
For time lapse experiments, actin dynamics within differentiating control cell line 
#3 NPCs were recorded using the 488nm laser of the ZEISS LSM 700 confocal at 20X 
total magnification. Two locations within each treatment group well were imaged every 
10 minutes for 20 hours for a total of 120 images per location and 240 images per 
treatment group. The images were then examined to determine how long five random 
neurites per location (10 different neurites per treatment group) protruded before 
beginning to retract, referred to as neurite persistence. Furthermore, the measuring tool 
of ImageJ 1.51 j8 was utilized to measure the length of five random neurites per location 
(10 different neurites per treatment group) throughout the entirety of neurite protrusion 
and retraction events. Instantaneous protrusion and retraction rates were then 
calculated using the change of neurite length divided by the time elapsed between each 
frame. For example, a 10μm increase in neurite length between t=10min and t=20 min 
would be an average instantaneous protrusion rate of 1μm/min or 60μm/hr. A 10μm 
decrease in neurite length between t=10 min and t=20 min would be an average 
instantaneous retraction rate of 1μm/min or 60μm/hr. 
 
For ‘mini-brain’ analyses, immunofluorescently stained ‘mini-brains’ were imaged 
using 405nm, 488nm, 555nm, and 639nm lasers of the ZEISS LSM 700 confocal at 20X 
total magnification. The area of various proteins was then analyzed within ten circular 
regions of 100μm in diameter around the edge of each ‘mini-brain.’ 
 





Statistical analyses were performed using SigmaPlot 13.0. For hIPSC-derived 
neuron analyses, data was first tested for normality using Kolmogorov-Smirnov tests. 
After rejection of the null hypothesis, non-parametric data was analyzed using Kruskal-
Wallis tests, a one-way analysis of variance (ANOVA) based on ranks. Following rejection 
of the Kruskal-Wallis null hypothesis, a pairwise multiple comparison post hoc Dunn’s 
tests were used to test for statistically significant differences among treatment groups. 
 
For ‘mini-brain’ analyses, data was first tested for normality using Shapiro-Wilk 
tests. After rejection of the null hypothesis, non-parametric data was analyzed using 
Mann-Whitney Rank Sum tests to test for statistical significance. Error bars represent 




CHAPTER 3: RESULTS 
 
Y-27632-mediated ROCK Inhibition Decreases RLC Phosphorylation (2D) 
 
To confirm the effectiveness of the Rho-Kinase (ROCK) inhibitor Y-27632 in 
human-induced pluripotent stem cell (hIPSC)-derived neurons, control cell line #2 human 
neurons were treated with Y-27632 for the first 24 hours of differentiation, and were then 
fixed and stained with DAPI to identify nuclei, β-III Tubulin to identify neurons, 
phosphorylated (S19/S20) myosin light chain/regulatory Light Chain (pRLC) to identify 
phosphorylation and activation of the ROCK substrate non-muscle myosin II (NM-II), and 
myosin light chain/regulatory light chain (RLC) to identify both phosphorylated (active) 
and non-phosphorylated (inactive) NM-II. Given the fact ROCK phosphorylates NM-II and 
Y-27632 is a ROCK inhibitor [Diagram 4A], we expect to see a Y-27632 dose-dependent 
decrease in the ratio of pRLC intensity (active NM-II) normalized to RLC intensity (active 
and inactive NM-II) in hIPSC-derived neurons.  
 
Normalized to the control treatment group, the average ratio of pRLC to RLC 
average neurite intensity in neurons significantly decreased by 2.18%, 7.23%, 11.06%, 
and 20.17% in 5μM, 10μM, 25μM, and 50μM Y-27632 24-hour treatment groups, 
respectively (Figure 1A). Similarly, the average ratio of pRLC to RLC in cell bodies of 
neurons, normalized to the control group, significantly decreased by 2.14%, 10.78%, 
7.70%, and 22.20% in 5μM, 10μM, 25μM, and 50μM Y-27632 24-hour treatment groups, 
respectively (Figure 1B). As expected, these results reveal a Y-27632 dose-dependent 
inhibition of ROCK and its phosphorylation and subsequent activation of NM-II. Therefore, 


































Figure 1. Y-27632 Significantly Decreases ROCK-mediated NM-II Activation. (A) 
Average pRLC vs. total RLC intensity, represented as percent of control, in neurites of 
control cell line #2 hIPSC-derived neurons following either 5μM, 10μM, 25μM, or 50μM 
Y-27632 treatment and 24-hour neural differentiation. (B) Average pRLC vs. total RLC 
intensity, represented as percent of control, in cell bodies of control cell line #2 hIPSC-
derived neurons following either 5μM, 10μM, 25μM, or 50μM Y-27632 treatment and 24-
hour neural differentiation. (See Table 7 in Appendix C for multiple comparison p values) 





Y-27632 Promotes Neurite Formation, Elongation, and Branching (2-D) 
 
 Human-induced (hIPSC)-derived neurons were utilized to further characterize the 
effects of Y-27632-mediated ROCK inhibition on neurite formation. Control cell lines #1, 
#2, and #3 human neurons were treated with Y-27632 for the first 24 hours of 
differentiation, and were then fixed and stained with β-III Tubulin to identify neurons, and 
DAPI to identify nuclei. Y-27632 treatment groups for all three cell lines visually appear 
to have more neuronal cells with increased neurite length and branching as compared to 
the control (Figure 2A, 2B, 2C).  
 
Normalized to the control, the average percent of neuronal cells in control cell line 
#1 hIPSC-derived neurons significantly increased by 33.71%, 42.13%, 33.86%, and 
37.85% in 5μM, 10μM, 25μM, and 50μM Y-27632 treatment groups, respectively (Figure 
3A). Normalized to the control, the average percent of neuronal cells in control cell line 
#2 hIPSC-derived neurons significantly increased by 41.69%, 68.74%, 66.35%, and 
70.47% in 5μM, 10μM, 25μM, and 50μM Y-27632 treatment groups, respectively (Figure 
3B). Normalized to the control, the average percent of neuronal cells in control cell line 
#3 hIPSC-derived neurons significantly increased by 15.81%, 18.54%, 19.29%, and 
18.66% in 5μM, 10μM, 25μM, and 50μM Y-27632 treatment groups, respectively (Figure 
3C). These results reveal a trend of a Y-27632 dose-dependent increase in average 
percent of neuronal cells until plateauing at 10μM in all three cell lines.  
 
Furthermore, Y-27632 increased the number of neurites in these neuronal cells. 
Normalized to the control, the average number of neurites per neuron in control cell line 




50μM Y-27632 treatment groups, respectively (Figure 4A). Moreover, normalized to the 
control, the average number of neurites per neuron in control cell line #1 hIPSC-derived 
neurons insignificantly increased by 4.88% and 4.26% in 5μM and 25μM Y-27632 
treatment groups, respectively (Figure 4A). Normalized to the control, the average 
number of neurites per neuron in control cell line #2 hIPSC-derived neurons significantly 
increased by 5.13%, 11.63%, 11.60%, and 13.29% in 5μM, 10μM, 25μM, and 50μM Y-
27632 treatment groups, respectively (Figure 4B). Normalized to the control, the average 
number of neurites per neuron in control cell line #3 hIPSC-derived neurons significantly 
increased by 9.18%, 10.76%, 9.44%, and 12.61% in 5μM, 10μM, 25μM, and 50μM Y-
27632 treatment groups, respectively (Figure 4C). With the exception of 5μM and 25μM 
Y-27632 treatment groups of control cell line #1 hIPSC-derived neurons, these results 
reveal a trend of a Y-27632 dose-dependent increase in average number of neurites per 
neuron until plateauing at 10μM in all three cell lines.  
 
In addition to increasing neurite formation, Y-27632 also increased neurite length. 
Normalized to the control, the average neurite length of control cell line #1 hIPSC-derived 
neurons significantly increased by 17.85%, 30.71%, 26.95%, and 32.54% in 5μM, 10μM, 
25μM, and 50μM Y-27632 treatment groups, respectively (Figure 5A). Normalized to the 
control, the average neurite length of control cell line #2 hIPSC-derived neurons 
significantly increased by 23.00%, 39.00%, 37.64%, and 43.67% in 5μM, 10μM, 25μM, 
and 50μM Y-27632 treatment groups, respectively (Figure 5B). Normalized to the control, 
the average neurite length of control cell line #3 hIPSC-derived neurons significantly 
increased by 20.98%, 29.06%, 33.41%, and 39.92%% in 5μM, 10μM, 25μM, and 50μM 




27632 dose-dependent increase in neurite length that plateaued at 10μM in all three cell 
lines.  
 
The significant increase in average percent of neuronal cells, number of neurites 
per neuron, and neurite length exhibited in hIPSC-derived neurons can in part be 
explained by the same molecular mechanism. ROCK1 and ROCK2 phosphorylate and 
activate NM-II, leading to the formation of actomyosin filament bundles capable of 
generating contractile forces [Diagram 4].  Moreover, ROCK1 and ROCK2 further 
promote NM-II activation and actomyosin filament bundle formation by inhibiting MLCP 
[Diagram 4]. Since Y-27632 inhibits ROCK-mediated activation of NM-II (Figure 1), less 
actomyosin filament bundles are formed. Consequently, Y-27632 treated hIPSC-derived 
neurons may produce weaker NM-II-driven contractile forces that would typically cause a 
neurite precursor to retract towards the cell body. Instead more neurite precursors may 
persist (Figure 7, 8A), which possibly explains the Y-27632-mediated increase in average 
percent of neuronal cells and average number of neurites per neuron. Furthermore, 
ROCK2 is also known to inhibit Rac-driven actin polymerization [39]. Hence, neurites of 
Y-27632 treated hIPSC-derived neurons may express increased Rac1 activity leading to 
increased actin polymerization. Increased actin polymerization in combination with less 
NM-II-driven contractility via ROCK1 and ROCK2 inhibition, causes neurite precursors of 
Y-27632 treated hIPSC-derived neurons to become significantly longer.   
 
Förster resonance energy transfer (FRET) can be used to further support these 
hypotheses by measuring the potential decrease in NM-II forces associated with Y-27632 




be used to directly measure the potential increase in Rac activity. Additionally, western 
blots can be utilized to measure the potential differences in expression of proteins within 
the Rac-driven actin polymerization pathway.    
 
 Y-27632 further increased neuronal complexity by increasing the number of 
branch points (the point where a neurite diverges into two). A trend of a Y-27632 dose-
dependent increase in average number of branch points was observed in all three cell 
lines until plateauing around 10μM. Normalized to the control treatment group, the 
average number of branch points in control cell line #1 hIPSC-derived neurons 
significantly increased by 58.86%, 75.36%, 59.09%, and 86.56% in 5μM, 10μM, 25μM, 
and 50μM Y-27632 treatment groups, respectively (Figure 6A). Normalized to the control 
treatment group, the average number of branch points in control cell line #2 hIPSC-
derived neurons significantly increased by 68.10%, 139.32%, 146.77%, and 164.51% in 
5μM, 10μM, 25μM, and 50μM Y-27632 treatment groups, respectively (Figure 6B). 
Normalized to the control treatment group, the average number of branch points in control 
cell line #3 hIPSC-derived neurons significantly increased by 52.09%, 70.48%, 73.10%, 
and 86.43% in 5μM, 10μM, 25μM, and 50μM Y-27632 treatment groups, respectively 
(Figure 6C).   
 
Future experiments are needed to determine the molecular mechanism of this 
significant increase. It is possible that Y-27632 may indirectly cause increased Rac1-
mediated ARP2/3 activity by increasing the activation of Wiskott–Aldrich Syndrome 
protein (WASP)-family proteins for example, leading to increased nucleation and 









































Figure 2. hIPSC-derived Neurons. Representative images of three different hIPSC-
derived neural progenitor cell lines differentiated for 24 hours following either 0μM 
(control), 5μM, 10μM, 25μM, or 50μM Y-27632 treatment. Cells were stained for neurons 
(β-III Tubulin, red) and nuclei (DAPI, blue). Insets included below each image with branch 
points identified (see white arrowheads). (A) Control cell line #1 hIPSC-derived neurons. 
(B) Control cell line #2 hIPSC-derived neurons. (C) Control cell line #3 hIPSC-derived 






























Figure 3. Y-27632 Significantly Increases Percent of Neuronal Cells. The average 
percent of neuronal cells in hIPSC-derived neurons that were treated with either 5μM, 
10μM, 25μM, or 50μM of Y-27632 and differentiated for 24 hours. (A) Control cell line #1 
hIPSC-derived neurons. (B) Control cell line #2 hIPSC-derived neurons. (C) Control cell 
line #3 mEGFP hIPSC-derived neurons. (n values provided in bar charts) (See Table 3 in 
Appendix B for absolute averages and Table 8 in Appendix C for multiple comparison p 
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Figure 4. Y-27632 Significantly Increases Number of Neurites per Neuron. The 
average number of neurites, represented as percent of control, in hIPSC-derived neurons 
that were treated with either 5μM, 10μM, 25μM, or 50μM of Y-27632 and differentiated 
for 24 hours. (A) Control cell line #1 hIPSC-derived neurons. (B) Control cell line #2 
hIPSC-derived neurons. (C) Control cell line #3 hIPSC-derived neurons. (n values 
provided in bar charts) (See Table 4 in Appendix B for absolute averages and Table 9 in 
Appendix C for multiple comparison p values) ( * p < 0.05, ** p < 0.001) Experiment 
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Figure 5. Y-27632 Significantly Increases Neurite Length. All three graphs represent 
the average neurite length in hIPSC-derived NPCs following treatment with either 0μM 
(control), 5μM, 10μM, 25μM, or 50μM of Y-27632 and a 24 hour period of differentiation. 
(A) Control cell line #1 hIPSC-derived neurons. (B) Control cell line #2 hIPSC-derived 
neurons. (C) Control cell line #3 hIPSC-derived neurons. (n values provided in tables 
inside of graphs) (See Table 5 in Appendix B for absolute averages and Table 10 in 






   A.                  B.  
   .  
 









  C.  












Figure 6. Y-27632 Significantly Increases Number of Branch Points. The average 
number of branch points, represented as percent of control, in hIPSC-derived neurons 
that were treated with either 5μM, 10μM, 25μM, or 50μM of Y-27632 and differentiated 
for 24 hours. (A) Control cell line #1 hIPSC-derived neurons. (B) Control cell line #2 
hIPSC-derived neurons. (C) Control cell line #3 hIPSC-derived neurons. (n values 
provided in bar charts) (See Table 6 in Appendix B for absolute averages and Table 11 
in Appendix C for multiple comparison p values) ( * p < 0.05, ** p < 0.001) Experiment 




Y-27632 Alters Neurite Dynamics (2-D)   
 
 To further understand the neurite dynamics underlying the observed increase in 
neuronal complexity as demonstrated by increased neurite number, length, and branch 
points in hIPSC-derived neurons, hIPSC-derived NPCs from control cell line #3 were 
imaged during neural differentiation. ActB of this control hIPSC-derived NPC line was 
previously gene-edited to express mEGFP, making this cell line ideal for following live 
actin dynamics within neurites and cell bodies during neural differentiation. Fluorescently 
labeling live cells, especially neurons, can be very troublesome due to cytotoxicity effects 
and low transfection efficiency. Thus, this cell line provides us with an invaluable tool to 
further investigate possibly altered actin dynamics within neurites of differentiating Y-
27632 treated NPCs.  
 
Still frames of time-lapse movies demonstrate increased neurite elongation in Y-
27632 treated differentiating NPCs compared to the control (Figure 7). Moreover, the 
dynamics of neurites in the control group appeared to be much more erratic as compared 
to neurites of Y-27632 treated groups. Specifically, the neurites seemed to protrude and 
retract much faster. Neurites of 5μM and 10μM Y-27632 treated groups on the other hand 
appeared to protrude at a slower rate and persist for much longer. Furthermore, when 
and if the neurites did retract, they did so at a seemingly slower rate.  
 
Control cell line #3 hIPSC-derived neurons treated with neural differentiation media 
only (control) exhibited an average neurite persistence (how long a neurite protrudes 
before beginning to retract) of 79min compared to 177min in 5μM Y-27632 treated 




this Y-27632-mediated increase in neurite persistence, time-lapse movies were further 
analyzed for rates of neurite protrusion and retraction. Neurites of control cell line #3 
hIPSC-derived neurons treated with neural differentiation media only (control) exhibited 
an average instantaneous protrusion rate of 34μm/hr compared to 21μm/hr in 5μM Y-
27632 treated neurons and 20μm/hr in 10μM Y-27632 treated neurons (Figure 8B). This 
reveals a significant decrease in neurite protrusion rates of Y-27632 treated hIPSC-
derived neurons. However, the Y-27632 treatment groups are not significantly different 
from one another. Control cell line #3 hIPSC-derived neurons treated with neural 
differentiation media only (control) exhibited an average instantaneous retraction rate of 
50μm/hr compared to 28μm/hr in 5μM Y-27632 treated neurons and 24μm/hr in 10μM Y-
27632 treated neurons (Figure 8C). This reveals a significant Y-27632 dose-dependent 
decrease in neurite retraction rates.  
 
These results support the proposed molecular mechanism underlying the 
observed significant increase in neurite number and neurite length of Y-27632 treated 
hIPSC-derived neurons. In summary, Y-27632-mediated ROCK inhibition may decrease 
NM-II-driven contractility and increase Rac-driven actin polymerization in hIPSC-derived 
neurons. Decreased NM-II-driven contractility is supported by the observation of 
decreased neurite retraction rates in Y-27632 treated hIPSC-derived neurons. A stronger 
NM-II-driven force would generate much faster neurite retraction rates similar to those 
observed in control neurons. Also, decreased NM-II-driven contractility may generate 
forces too weak to shorten some neurites more than they have lengthened via increased 
Rac-driven actin polymerization. This may give rise to neurite elongation and increased 




contractility via decreased phosphorylation of RLC (Figure 1) and increased Rac-driven 
actin polymerization in Y-27632 treated hIPSC-derived neurons.  
 
The Y-27632-mediated significant decrease in neurite protrusion rates is more 
difficult to explain. If Rac-driven actin polymerization levels are increased and there are 
weaker NM-II-driven retraction forces present, we would expect faster neurite protrusion 
rates. Given results of the contrary, we believe this is due to another effect of ROCK 
inhibition. ROCK2 is also known to promote adhesion maturation in cell protrusions, 
resulting in focal adhesion formation [16, 39, 55]. Therefore, Y-27632-mediated ROCK 
inhibition may be decreasing the number of focal adhesions in neurite protrusions.   
 
According to the “molecular clutch” hypothesis, actin filaments at the leading edge 
of a cell are “engaged” and immobilized when indirectly bound to transmembrane integrin 
proteins of the extracellular matrix (ECM) via focal adhesions [12]. Actomyosin-induced 
contractile forces are transmitted through these focal adhesions to the ECM, giving a cell 
traction [12]. As actin filaments polymerize at a cell’s leading edge, this allows a protrusion 
to form [12]. Contrastingly, in the absence of focal adhesions, actin filaments at the 
leading edge of a cell are “disengaged” with the ECM. As a result, traction forces are not 
generated and actomyosin-induced contractile forces instead cause actin retrograde flow, 
hindering cell protrusion events [12]. Thus, in the case of Y-27632 treated hIPSC-derived 
neurons, actin filaments may be “disengaged” from the ECM due to a lack of ROCK2-
mediated focal adhesion formation. Consequently, neurite protrusion events halt until 




protrusion rates (Figure 8B). Future experiments using ROCK isoform-specific 











































Figure 7. Neural Differentiation Time-Lapse. (A) Representative still frames of movies 
of neural differentiation of control cell line #3 hIPSC-derived NPCs gene-edited to express 
Actin mEGFP at 4, 8, 12, 16, and 20 hours following either 0μM (control), 5μM, or 10μM 
Y-27632 treatment. Insets included below each still frame. Y-27632 promotes neurite 

































Figure 8.  Y-27632 Significantly Increases Neurite Persistence and Significantly 
Decreases Neurite Protrusion and Retraction Rates. (A) Average persistence of 
neurites during 20 hour neural differentiation following treatment with either 0μM (control), 
5μM, or 10μM of Y-27632 in control cell line #3 hIPSC-derived NPCs (n=30). (B) Average 
instantaneous protrusion rate of neurites during 20 hour neural differentiation following 
treatment with either 0μM (control), 5μM, or 10μM of Y-27632 in control cell line #3 hIPSC-
derived NPCs (n values provided in graph). (C) Average instantaneous retraction rate of 
neurites during 20 hour neural differentiation following treatment with either 0μM (control), 
5μM, or 10μM of Y-27632 in control cell line #3 hIPSC-derived NPCs (n values provided 





Y-27632 Promotes Neurite Formation (3-D)  
 
To determine if Y-27632-mediated ROCK inhibition promotes neurite formation in 
a more physiologically-relevant ‘mini-brain’ model as in 2-D hIPSC-derived neurons, three 
sets of approximately 90 day old control cell line #4 hIPSC-derived human cortical 
organoids were fixed, cryosectioned, and stained for the early neuronal marker 
doublecortin (DCX) to identify neurites and DAPI to identify nuclei.  
 
Y-27632 treated ‘mini-brains’ visually appear to have more neurites as compared 
to control ‘mini-brains’ (Figure 9A). The average percent area of DCX normalized to DAPI 
significantly increased from 50.83% in control human cortical organoids to 124.80% in 
10μM Y-27632 treated human cortical organoids (Figure 9B). Thus, Y-27632 may be 
promoting the formation of neurites in 3-D just as in 2-D hIPSC-derived neurons. This 
may be due to both an increase in number of neurites per neuron, neurite length, and 
branching. 
 
The mechanism of this observation is likely due to the same proposed mechanism 
regarding the observed increase in number of neurites per neuron (Figure 4) and neurite 
length (Figure 5) in 2-D hIPSC-derived neurons. In 3-D, Y-27632-mediated ROCK1 and 
ROCK2 inhibition may decrease NM-II-driven contractility forces, resulting in an increase 
in neurite persistence as observed in 2-D hIPSC-derived neurons (Figure 7A). Increased 
neurite persistence leads to an increase in number of neurites per neuron. Furthermore, 
Y-27632-mediated ROCK2 inhibition may be upregulating Rac-driven actin 









































Figure 9. Y-27632 Significantly Increases Neurite Area. (A) 90 day old cerebral 
organoids treated with 10 μM Y-27632 overnight. ‘Mini-brains’ were cryosectioned and 
stained for the early neuronal marker, doublecortin (DCX, green), to label neurites, and 
the nuclei marker, DAPI (blue).  (B) Y-27632 significantly increases the percent area of 
DCX normalized to DAPI (n=30, 2.5π mm2 regions). Experiment repeated three times. ** 






Y-27632 Remodels Excitatory Synapses (3-D) 
 
To determine whether or not Y-27632 can be used to alter synaptic connections, 
three sets of approximately 90 day old control cell line #4 hIPSC-derived human cortical 
organoids were fixed, cryosectioned, and stained for the presynaptic excitatory synaptic 
marker vesicular glutamate transporter 1 (Vglut-1) and DAPI to identify nuclei.  
 
Y-27632 treated ‘mini-brains’ visually appear to have more Vglut-1 expression as 
compared to control ‘mini-brains’ (Figure 10A). The average percent of Vglut-1 area 
normalized to DAPI significantly increased from 12.44% in control human cortical 
organoids to 46.00% in 10μM Y-27632 treated human cortical organoids (Figure 10B). 
Therefore, Y-27632 increases the density of excitatory synapses.  
 
This result was very surprising at first. NM-II-driven contractility is necessary for 
bundling and contracting actin filaments, causing polarization and maturation of the 
dendritic spine head in 2-D rat hippocampal neurons [40]. Therefore, we initially 
hypothesize that less NM-II-driven contractility, via Y-27632-mediated ROCK1 and 
ROCK2 inhibition, would result in the formation of less mature mushroom shaped 
dendritic spines and excitatory synapses.  
 
Given results to the contrary, RNA-Seq analysis of human cortical organoids was 
examined and we discovered that the ‘mini-brains’ preferentially expressed ROCK2 as 
opposed to ROCK1. Hence, we are inhibiting ROCK2 activity more than ROCK1 activity. 
Since ROCK2 is also known to inhibit Rac-driven actin polymerization [39], we may be 




Although the dendritic spines of these Y-27632 treated ‘mini-brains’ may not be of the 
mature mushroom-shaped morphology, the spines heads may be larger due to increased 
Rac-driven actin polymerization [39, 52, 61]. This would give rise to an increase in 
excitatory synaptic area, as observed in the 10μM Y-27632 treated human cortical 
organoids. Further experiments exploring the Rac-driven actin polymerization pathway 
were completed to support this hypothesis.  
 









































Figure 10. Y-27632 Significantly Increases Excitatory Synapse Area. (A) 90 day old 
‘mini-brains’ were treated with 10μM Y-27632 for 24 hours. ‘Mini-brains’ were 
cryosectioned and stained with Vglut-1 (magenta) to identify excitatory synaptic contacts 
and pRLC (green) to identify phosphorylation of the ROCK substrate. (B) Y-27632 
significantly increases the percent area of Vglut-1 normalized to DAPI (n=30, 2.5π mm2 





Y-27632 Increases Rac-driven Actin Polymerization (3-D) 
 
 To further support the hypothesis that increased Rac-driven actin polymerization 
drives the increase in excitatory synapse area, three sets of approximately 90 day old 
control cell line #4 hIPSC-derived human cortical organoids were fixed, cryosectioned, 
and stained for total LIM-Kinase 1 (LIMK), phosphorylated LIMK-Kinase 1 (pLIMK), and 
DAPI. Another three sets of approximately 90 day old hIPSC-derived human cortical 
organoids were fixed, cryosectioned, and stained for total cofilin, phosphorylated cofilin 
(pCofilin), and DAPI. 
 
In the Rac-driven actin polymerization pathway, Rac1 activates p21-activated 
kinase (PAK) [25, 32] which phosphorylates and activates LIMK [Diagram 6] [10]. 
Subsequently, activated LIMK phosphorylates the actin severing protein cofilin to form 
pCofilin Ser3 [Diagram 6] [30]. This inhbits cofilin from associating with actin, leading to 
decreased actin turnover and increased actin polymerization [Diagram 6] [9]. Since we 
expect increased Rac-driven actin polymerization via Y-27632-mediated ROCK2 
inhibition, we should see an increased ratio of percent area of pLIMK versus total LIMK 
in Y-27632 treated mini-brains [Diagram 6]. Furthermore, we should observe an 











Y-27632 treated ‘mini-brains’ visually appear to have more pLIMK vs. total LIMK 
expression as compared to control ‘mini-brains’ (Figure 11A). The average percent area 
of pLIMK vs. total LIMK increased significantly from 23.77% in control human cortical 
organoids to 241.01% in 10μM Y-27632 treated human cortical organoids (Figure 11B). 
These results support the hypothesis of increased LIMK activity in the Rac-driven actin 
polymerization pathway. Note, the average percent area of pLIMK vs. total LIMK in 10μM 
Y-27632 treated human cortical organoids may be above 100% due to a stronger binding 
affinity of the pLIMK antibody compared to the LIMK antibody.  
 
Y-27632 treated ‘mini-brains’ also visually appear to have more pCofilin vs. total 
cofilin expression as compared to control ‘mini-brains’ (Figure 12A). The average percent 
area of pCofilin vs. total cofilin increased significantly from 54.36% in control human 
cortical organoids to 93.07% in 10μM Y-27632 treated human cortical oganoids (Figure 
12B). These results support the hypothesis of decreased cofilin activity in the Rac-driven 
actin polymerization pathway.  
 
Together, these results provide evidence of a Y-27632-mediated increase in Rac-
driven actin polymerization. Increased Rac-driven actin polymerization may cause 
expansion of the dendritic spine head, underlying the observed significant increase in the 










































Figure 11. Y-27632 Significantly Increases LIMK Activation. Y-27632 stimulates Rac 
activation, leading to LIMK phosphorylation and activation. (A) 90 day old ‘mini-brains’ 
were treated with 10μM Y-27632 for 24 hours. ‘Mini-brains’ were cryosectioned and 
stained with pLIMK (green) and total LIMK (magenta). (B) Y-27632 significantly increases 
the percent area of pLIMK to total LIMK (n=30, 2.5π mm2 regions). Experiment repeated 











































Figure 12. Y-27632 Significantly Decreases Cofilin Activation. Y-27632 promotes 
actin polymerization and stabilization via phosphorylation and inactivation of Cofilin by 
activated LIMK. (A) 90 day old ‘mini-brains’ were treated with 10μM Y-27632 for 24 hours. 
‘Mini-brains’ were cryosectioned and stained for pCofilin Ser3 (magenta) and total Cofilin 
(green). (B) Y-27632 significantly increases the percent area of pCofilin Ser3 to total 




CHAPTER 4: DISCUSSION 
 
Autism spectrum disorder (ASD) is a genetically complex heterogeneous 
neurodevelopmental disorder in which patients exhibit social deficits in both verbal and 
non-verbal forms of communication and display restricted and repetitive behaviors [2]. 
The etiology is unknown, but recent evidence suggests Autistic patients have increased 
densities of dendritic spines and increased numbers of excitatory to inhibitory synaptic 
connections, referred to as an E/I imbalance [42]. We sought to decrease this E/I 
imbalance in ASD patients by targeting the actin motor protein non-muscle myosin II (NM-
II) due to its pivotal role of polarizing dendritic spines into a mature mushroom-shaped 
morphology, leading to synapse formation [Diagram 3] [16, 33, 39, 44]. Since the RhoA 
kinase serine/threonine effector Rho-Kinase (ROCK) phosphorylates and activates NM-
II [1], we utilized a pan-ROCK inhibitor, Y-27632, to downregulate NM-II activity and 
potentially reduce the number of synaptic connections.  
 
In this thesis work we utilized a more physiologically-relevant 3-D human cortical 
organoid (‘mini-brain’) model to explore the potential of Y-27632 as an ASD therapeutic 
and to improve our understanding of the mechanisms that underlie the formation of 
synaptic circuits. A recent study showed Y-27632 treatment of rat hippocampal neurons 
to increase the formation of filopodia-like spines [16]. Therefore, we hypothesized Y-
27632-mediated ROCK inhibition would decrease synaptic connections in control ‘mini-
brains.’  Surprisingly, acute Y-27632 treatment of ‘min-brains’ revealed an increase in 





To begin to explain this unexpected result, we analyzed control ‘mini-brain’ RNA-
Seq data, which revealed a higher expression of the ROCK2 isoform as opposed to the 
ROCK1 isoform. Hence, we are inhibiting a higher level of ROCK2 as compared to 
ROCK1 with the isoform-nonselective ROCK inhibitor Y-27632. In addition to activating 
NM-II, ROCK2 inhibits Rac-driven actin polymerization [39], So we may be increasing 
Rac-driven actin polymerization levels within the ‘mini-brains’. Increased Rac-driven actin 
polymerization would cause expansion of the dendritic spine head, underlying the 
observed increase in excitatory synapse area (Figure 10).  
 
To provide support for this hypothesis, we explored the Rac-driven actin 
polymerization pathway. We observed an increase in the area of phosphorylated LIMK-
Kinase 1 (pLIMK) versus total LIMK-Kinase 1 (LIMK) (Figure 11) and phosphorylated 
cofilin (pCofilin) versus total cofilin (Figure 12) in the ‘mini-brains’. In the Rac-driven actin 
polymerization pathway, pLIMK phosphorylates the actin severing protein cofilin to form 
pCofilin [30]. This inhbits cofilin from associating with actin, leading to decreased actin 
turnover and increased actin polymerization [9]. Therefore, these results provide evidence 
of increased Rac-driven actin polymerization.  
 
This hypothesis is further supported by a recent study in rat hippocampal neurons 
by Newell-Litwa et al. that revealed a ROCK2 knockdown-mediated increase in spine 
head size and excitatory synapse area as compared to ROCK1 knockdowns [39]. 
Interestingly, these ROCK1 knockdown neurons are morphologically similar to those 
observed by Hodges et al. in Y-27632 treated rat hippocampal neurons [16, 39]. Although 




than ROCK2. If using rat hippocampal neurons as a model, this mistakenly provides 
further support for Y-27632 as a potential therapeutic in ASD patients. This demonstrates 
the need for physiologically-relevant brain models, such as ‘mini-brains’ to assess the 
impact of drug therapies on developing neural circuits.  
 
In addition to altered synaptic connectivity, ASD patients express defective neurite 
formation [31]. Since ROCK inhibitors have been shown to increase neurite formation in 
many different 2-D cell cultures [13, 21, 29, 36, 46, 57], Y-27632 could potentially serve 
to rescue defective neurite formation in ASD patients. We first confirmed previous findings 
of a ROCK inhibitor-mediated increase in neurite formation using a human-induced 
(hIPSC)-derived neuron model. In this 2-D control cell model, we showed a Y-27632-
mediated dose-dependent increase in the percent of neuronal cells (Figure 3), number of 
neurites per neuron (Figure 4), neurite length (Figure 5), and number of branch points per 
neurite (Figure 6).  
 
In order to better understand the neurite dynamics and molecular mechanisms 
underlying these observed increases, we used a hIPSC-derived neuronal cell line 
previously gene-edited to express mEGFP to track neurite protrusion and retraction rates. 
The neurites of Y-27632 treated neurons protruded and retracted at a slower rate (Figures 
7, 8B, 8C), leading to increased neurite persistence (Figures 7, 8A). We hypothesize 
slower retraction rates are due to decreased NM-II-driven contractile forces via ROCK1 
and ROCK2 inhibition, while slower protrusion rates are due to decreased adhesion 





We also examined the effects of Y-27632 on neurite formation in the more 
physiologically-relevant 3-D ‘mini-brain’ model. Acute Y-27632 treatment of control ‘mini-
brains’ revealed an increase in area occupied by neurites (Figure 9). Therefore, Y-27632 
increases neurite formation in 3-D just as in 2-D. These results support previous findings 
of the effects of ROCK inhibition on neurite formation and provide support for the potential 
of ROCK inhibitors as an ASD therapeutic during early neurite formation. 
 
Although Y-27632-mediated ROCK inhibition increased neurite formation, it also 
increased excitatory synapses as mentioned previously. Together, these findings suggest 
Y-27632 would not serve as a potential therapeutic for ASD since we seek to decrease 
the number of excitatory connections in ASD patients. Instead, ROCK1 isoform-selective 
inhibitors may provide the answer. As observed by Newell-Litwa et al., rat hippocampal 
neurons exhibit a ROCK1 knockdown-mediated decrease in spine head size and 
excitatory synapse area as compared to ROCK2 knockdowns [39]. However, ROCK2 is 
more highly expressed in the developing human brain and brain organoids when 
compared to ROCK1 [Diagram 9] [22, 23, 43].  Thus, unlike rat hippocampal neurons, Y-
27632 increases excitatory synapse area in brain organoids (Figure 10) consistent with 
knockdown of ROCK2.  Therefore, a ROCK1 isoform-selective inhibitor may decrease 
the number of excitatory connections in ASD patients as opposed to pan-ROCK inhibitors 
such as Y-27632, that also inhibit ROCK2.  
 
Despite the lack of evidence for Y-27632 as a potential ASD therapeutic, Y-27632 
poses many other applications. Since Y-27632 increased the number of excitatory 




ASD patients. Thus, Y-27632 treated ‘mini-brains’ could be used as an alternative Autistic 
model for drug and gene therapies. Our current understanding of idiopathic Autism stems 
mainly from genomic analyses of blood and post-mortem patient brain samples [19, 26, 
35, 37, 48, 58] and genetically modified mice models [37, 49]. However, the limited 
sample size of patient samples poses limitations. Furthermore, inherent genetic 
differences between mice and human brain circuits pose complications in applicability of 
conclusions drawn from ASD mice models [7, 37]. Alternatively, Y-27632 treated ‘mini-
brains’ provide us with an applicable human-based and 3-D physiologically-relevant 
Autistic phenotypic cell model that requires limited sample sizes obtained by non-invasive 
methods.  
 
Moreover, Y-27632 could potentially be used as a therapeutic in conditions where 
neural connections are lacking or lost, such as schizophrenia and Alzheimer’s disease. 
Y-27632 may increase neural connectivity in these diseases, particularly at the level of 
both neurites and synapses by the proposed mechanisms depicted in Diagrams 7 and 8 
in Appendix D. Lastly, Y-27632 could potentially be used to lower elevated 
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Table 5. Figure 5 Average Neurite Length (μm) 
 
Group Figure 4A Figure 4B Figure 4C 
Control 
 
1.47 1.45 1.53 
5μM 
 
1.46 1.49 1.68 









 50μM 1.50 1.58 1.73 
Group Figure 3A Figure 3B Figure 3C 
Control 
 
43.96 51.47 62.94 
5μM 
 
59.43 67.18 72.91 









 50μM 64.04 74.28 74.74 
Group Figure 5A Figure 5B Figure 5C 
Control 
 
29.97 38.64 29.18 
5μM 
 
33.30 46.26 35.28 









 50μM 38.00 51.50 40.80 
 














Table 6. Figure 6 Average Number of Branch Points 
 
Group Figure 6A Figure 6B Figure 6C 
Control 
 
0.34 0.53 0.31 
5μM 
 
0.38 0.69 0.47 






















































Table 8. Figure 3 p Values. ** p < 0.001 * p < 0.05 
 
 
Comparison Figure  1A Figure 1B 










 50μM vs. 10μM <0.001** 
 
<0.001** 


































Comparison Figure 3A Figure 3B Figure 3C 





















































































































Table 10. Figure 5 p Values. ** p < 0.001 * p < 0.05 
 
Comparison Figure 5A Figure 5B Figure 5C 














 50μM vs. 10μM 1.000 0.177 <0.001** 



















 25μM vs. 10μM 
 
0.056 0.196 <0.001** 




















Comparison Figure 4A Figure 4B Figure 4C 



























































































Table 11. Figure 6 p Values. ** p < 0.001 * p < 0.05 
 
Comparison Figure 6A Figure 6B Figure 6C 














 50μM vs. 10μM 0.154 <0.001** 
 
<0.001** 


























































































Diagram 7. Y-27632 Increases Rac-driven Actin Polymerization. ROCK2 inhibits Rac-
driven actin polymerization. Thus, Y-27632-mediated ROCK2 inhibition causes 
upregulation of the Rac-driven actin polymerization pathway. In particular, increased 
LIMK-1 activity leads to phosphorylation and inactivation of the actin severing protein 
cofilin, promoting actin stabilization and polymerization. In 2-D hIPSC-derived neurons 
and 3-D ‘mini-brains’, this promotes neurite formation. In 3-D ‘mini-brains’, this 
mechanism increases excitatory synapse area by increasing the size of the dendritic 
spine head.  
2-D & 3-D 3-D 
 





































Diagram 8. Y-27632 Decreases NM-II-driven Contractility. Y-27632-mediated ROCK1 
and ROCK2 inhibition downregulates NM-II activity, leading to less actomyosin-driven 
contractility forces. In 2-D hIPSC-derived neurons and 3-D ‘mini-brains’, this promotes 
neurite formation. In 3-D ‘mini-brains’, this mechanism results in less mature mushroom- 
shaped dendritic spines. 
 















































Diagram 9. ROCK1 vs. ROCK2 Expression in the Human Neocortex. [Retrieved 
from hbatlas.org] [22, 23, 43]
 
 
 
 
